| 101 |
25331939 | Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies. | 2014 Dec |
3 |
| 102 |
25426931 | Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells. | 2014 |
1 |
| 103 |
25621010 | Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case. | 2014 |
2 |
| 104 |
22845311 | Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. | 2013 Mar |
1 |
| 105 |
23065514 | The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. | 2013 May |
1 |
| 106 |
23098068 | Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance. | 2013 Jun |
1 |
| 107 |
23218026 | Imatinib and Nilotinib inhibit Bcr-Abl-induced ROS through targeted degradation of the NADPH oxidase subunit p22phox. | 2013 Feb |
3 |
| 108 |
23247657 | The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib. | 2013 Mar 21 |
2 |
| 109 |
23273517 | Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors. | 2013 Feb 1 |
2 |
| 110 |
23372106 | Treating chronic myeloid leukemia: improving management through understanding of the patient experience. | 2013 Feb |
2 |
| 111 |
23383600 | Surrogate end points for long-term outcomes in chronic myeloid leukemia. | 2013 Oct |
1 |
| 112 |
23433665 | Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. | 2013 Aug 4 |
1 |
| 113 |
23502220 | Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. | 2013 May 2 |
2 |
| 114 |
23546518 | Haematological cancer: Nilotinib reduces emergence of BCR-ABL mutations in CML. | 2013 May |
1 |
| 115 |
23552567 | A case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib. | 2013 Mar |
1 |
| 116 |
23707608 | Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. | 2013 Oct 1 |
1 |
| 117 |
23787070 | Bcr-Abl tyrosine kinase inhibitors- current status. | 2013 Jun 20 |
1 |
| 118 |
23787811 | Tyrosine kinase inhibition facilitates autophagic SNCA/α-synuclein clearance. | 2013 Aug |
1 |
| 119 |
23906052 | New insights into biology of chronic myeloid leukemia: implications in therapy. | 2013 Sep |
1 |
| 120 |
24091670 | PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor. | 2013 Oct 3 |
2 |
| 121 |
24095296 | A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase. | 2013 Dec |
1 |
| 122 |
24130846 | A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL. | 2013 |
1 |
| 123 |
24155950 | Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells. | 2013 |
1 |
| 124 |
24236021 | Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study. | 2013 |
1 |
| 125 |
21565522 | Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. | 2012 May |
1 |
| 126 |
21717440 | Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia. | 2012 Jan 15 |
1 |
| 127 |
21732337 | Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. | 2012 Jan 1 |
1 |
| 128 |
21840128 | Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. | 2012 May |
1 |
| 129 |
21844872 | Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. | 2012 Feb |
2 |
| 130 |
21874302 | The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors. | 2012 Feb |
1 |
| 131 |
21892207 | c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. | 2012 Apr 5 |
1 |
| 132 |
22076466 | Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. | 2012 Jun |
2 |
| 133 |
22089930 | Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. | 2012 Feb |
1 |
| 134 |
22157807 | Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. | 2012 May |
1 |
| 135 |
22262141 | Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. | 2012 Feb |
1 |
| 136 |
22399151 | Recurrent bone marrow aplasia secondary to nilotinib in a patient with chronic myeloid leukemia: a case report. | 2012 Dec |
2 |
| 137 |
22493660 | Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. | 2012 |
1 |
| 138 |
22517301 | Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. | 2012 Nov 1 |
1 |
| 139 |
22554713 | Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells. | 2012 Oct 28 |
3 |
| 140 |
22570081 | Molecular interactions of c-ABL mutants in complex with imatinib/nilotinib: a computational study using linear interaction energy (LIE) calculations. | 2012 Sep |
3 |
| 141 |
22608253 | Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. | 2012 May 18 |
2 |
| 142 |
22633167 | Nilotinib-associated vascular events. | 2012 Oct |
1 |
| 143 |
22745749 | Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells. | 2012 |
1 |
| 144 |
22956142 | An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents. | 2012 |
2 |
| 145 |
22985168 | Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. | 2012 Sep 17 |
1 |
| 146 |
23055606 | Nilotinib based pharmacophore models for BCRABL. | 2012 |
3 |
| 147 |
23090888 | Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. | 2012 Nov |
2 |
| 148 |
23238683 | All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib. | 2012 Dec |
1 |
| 149 |
23285088 | Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells. | 2012 |
1 |
| 150 |
23363745 | [K562 cell line resistance to nilotinib induced in vitro and preliminary investigation of its mechanisms]. | 2012 Nov |
1 |